ASX-Dividend-Report-Banner

Avasa raises $1.55M in oversubscribed funding round with innovative implantable devices

September 14, 2023 06:50 AM AEST | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 Avasa raises $1.55M in oversubscribed funding round with innovative implantable devices
Image source: Kalkine Media

MIAMI and AUCKLAND, New Zealand, Sept. 14, 2023 /PRNewswire/ -- Avasa, a medical device pioneer advancing surgical techniques for improved patient outcomes, announces the successful completion of its recent funding, raising an impressive $1.55 million in capital investment. The influx of new investment comes from New Zealand Growth Capital Partners, Pacific Channel, Booster Innovation Fund, Brisbane Angels, and Cure Kids Ventures, whose support augments existing investors Bridgewest Group, and Uniservices, the investment arm of the University of Auckland.

"We are thrilled to receive overwhelming support from both new and existing investors. With these additional resources we can accelerate our go-to-market efforts. We have hired a top-tier quality assurance manager, launched the second phase of our market validation survey to support our Series A raise, are finalizing product development, scaling up manufacturing, and collecting data from our animal trials ahead of our US FDA 510K submission in early 2025. In the next year, we aim to set up relationships with preferred distributors for the US market," says Dr. Nandoun Abeysekera, CEO and Founder of Avasa.

The high interest in capital support affirms the investment community's confidence in Avasa's scientific approach to transforming procedures in reconnecting veins and arteries in reconstructive microsurgery. "Currently, surgeons face the challenge of tediously hand-sewing micro arteries to re-establish blood flow to transplanted tissues. This manual method is not only intricate and risk-laden, but also consumes 40-60 minutes for just one arterial connection. Our innovative implant makes microvascular surgery quicker and safer. We are empowering surgeons to securely and efficiently link microvascular arteries in under 10 minutes, positioning us as the next standard of care," says Dr. Abeysekera.

Jacques Richter, Associate Investment Director, New Zealand Growth Capital Partner adds, "we are excited to join Nandoun and the Avasa team on their journey to change reconstructive microsurgery. Throughout our due diligence process, we were impressed by Nandoun's deep understanding and personal connection to the problem being solved. This is evidenced in the elegant coupler design that the Avasa team has developed which provides clear value to surgeons."

In the future, Dr. Abeysekera expects the scope of Avasa's device to expand to other surgical fields such as organ transplants, cardiothoracic surgery and vascular surgery. "We want to keep innovating at the intersection of medicine, design, and engineering to improve health outcomes for people," says Dr. Abeysekera.

About Avasa
Avasa is a medical device company dedicated to revolutionizing surgical procedures through innovative implantable devices. Avasa's mission is to transform reconstructive microsurgery and help patients who've suffered debilitating disease and deformity.

Media Contacts:

U.S. Jenny Bourbiel, [email protected]
New Zealand Dr. Nandoun Abeysekera, [email protected]

Logo - https://mma.prnasia.com/media2/2209013/avasa_Logo.jpg?p=medium600


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.